[go: up one dir, main page]

AR069802A1 - Compuestos de carbamoilo como inhibidores de dgat1 190 - Google Patents

Compuestos de carbamoilo como inhibidores de dgat1 190

Info

Publication number
AR069802A1
AR069802A1 ARP080105523A ARP080105523A AR069802A1 AR 069802 A1 AR069802 A1 AR 069802A1 AR P080105523 A ARP080105523 A AR P080105523A AR P080105523 A ARP080105523 A AR P080105523A AR 069802 A1 AR069802 A1 AR 069802A1
Authority
AR
Argentina
Prior art keywords
ring
alkyl
alkoxy
carbon atom
optionally substituted
Prior art date
Application number
ARP080105523A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069802A1 publication Critical patent/AR069802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen compuestos inhibidores de DGAT-1 de la formula (1), sales y prodrogas farmacéuticamente aceptables de los mismos, conjuntamente con composiciones farmacéuticas, y su uso en el tratamiento, por ejemplo, de la obesidad. Reivindicacion 1: Un compuesto de la formula (1), o una sal, o prodroga farmacéuticamente aceptable del mismo, en donde El anillo A es 2,6-pirazindiilo, 3,5-piridindiilo o 2,6-piridindiilo, cada uno opcionalmente sustituido sobre un átomo de carbono disponible con uno o dos sustituyentes independientemente seleccionados de alquilo C1-3 lineal, alquenilo C2-3; alquinilo C2-3; alcoxi C1-2, metoximetilo, amino y ciano; X es =O o =S; el anillo B es 1,4-fenileno o el anillo B es un anillo di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de piridindiilo, furandiilo, tiofendiilo, pirroldiilo, oxazoldiilo, tiazoldiilo, imidazoldiilo, isoxazoldiilo, isotiazoldiilo y pirazoldiilo; cada uno opcionalmente sustituido sobre un átomo de carbono disponible con uno o dos sustituyentes independientemente seleccionados de halo, amino, ciano, alquilo C1-4, alquenilo C2-3; alquinilo C2-3; alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; Y1 es un enlace directo entre el anillo B y el anillo C o Y1 es -O-, -S- o -NRa- en donde Ra es hidrogeno o alquilo C1-4; Y2 es -(CH2)r en donde r es 2 o 3, e Y2 está unido en el mismo átomo de carbono que Y1 en el anillo C e Y2 está unido a un átomo de carbono adyacente a Y1 en el anillo B; n es 0 o n es 1 cuando Y1 es un enlace directo entre el anillo B y el anillo C y cuando el anillo B es 1,4-fenileno y el anillo C es cicloalcano C4-6, de modo que se forme un sistema de anillos espiro de 5 o 6 miembros y el anillo C se encuentre tri-unido; el anillo C es un anillo o sistema de anillos di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de cicloalcano C4-6, bicicloalcano C7-10 y tricicloalcano C8-12 cada uno opcionalmente sustituido sobre un átomo de carbono disponible, incluyendo el átomo de carbono del anillo que porta al grupo que contiene a Z, con un sustituyente seleccionado de hidroxi, alquilo C1-4, alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; o el anillo C es un anillo di-unido (excluyendo las uniones a través de los mismos átomos o de átomos adyacentes) seleccionado de fenileno, piridindiilo, piperidindiilo N-unido a Y1, piperazindiilo, furandiilo, tiofendiilo, pirroldiilo, oxazoldiilo, tiazoldiilo, imidazoldiilo, isoxazoldiilo, isotiazoldiilo, pirazoldiilo y azabiciclo[3.1.0]hexandiilo; cada uno opcionalmente sustituido sobre un átomo de carbono disponible con hasta cuatro sustituyentes independientemente seleccionados de fluor, cloro, bromo, ciano, alquilo C1-4, alcoxi C1-4 y alcoxi C1-4-alquilo C1-4; L es un enlace directo al anillo C, -O-, -S- o -NH-; p es 0, 1 o 2 y cuando p es 1 RA1 y RA2 son cada uno independientemente hidrogeno o alquilo C1-4 o RA1 y RA2 están unidos conjuntamente para formar un anillo espiroalquilo C3-6; Z es carboxi o un mímico o bioisostero del mismo, hidroxi o -CONRbRc en donde Rb y Rc están independientemente seleccionados de hidrogeno y alquilo C1-4, cuyo grupo alquilo C1-4 puede estar opcionalmente sustituido con carboxi o un mímico o bioisostero del mismo; y en donde cualquier átomo de carbono en un grupo que contiene alquilo C1-3 lineal, alcoxi C1-2, alquilo C1-4 o alcoxi C1-4 definido precedentemente puede estar opcionalmente sustituido con hasta 3 átomos de fluor; con la condicion de que el compuesto ácido (4-(4-(6-carbamoil-piridin-2-il)fenil)ciclohexil)acético se encuentre excluido.
ARP080105523A 2007-12-20 2008-12-18 Compuestos de carbamoilo como inhibidores de dgat1 190 AR069802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1539707P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
AR069802A1 true AR069802A1 (es) 2010-02-17

Family

ID=40427160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105523A AR069802A1 (es) 2007-12-20 2008-12-18 Compuestos de carbamoilo como inhibidores de dgat1 190

Country Status (23)

Country Link
US (2) US7994179B2 (es)
EP (1) EP2234978B1 (es)
JP (1) JP5662803B2 (es)
KR (1) KR20100099738A (es)
CN (1) CN101932562B (es)
AR (1) AR069802A1 (es)
AU (1) AU2008339570B2 (es)
BR (1) BRPI0821274A2 (es)
CA (1) CA2707660A1 (es)
CL (1) CL2008003847A1 (es)
CO (1) CO6290685A2 (es)
CR (1) CR11518A (es)
DO (1) DOP2010000192A (es)
EA (1) EA201001015A1 (es)
EC (1) ECSP10010274A (es)
ES (1) ES2535083T3 (es)
IL (1) IL206045A0 (es)
NI (1) NI201000108A (es)
NZ (1) NZ586104A (es)
PE (1) PE20091682A1 (es)
TW (1) TW200932235A (es)
WO (1) WO2009081195A1 (es)
ZA (1) ZA201003979B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523133A (ja) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
EP2301923B1 (en) 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
ATE492541T1 (de) 2006-05-30 2011-01-15 Astrazeneca Ab Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
US8003676B2 (en) * 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
CN101460492A (zh) * 2006-06-08 2009-06-17 阿斯利康(瑞典)有限公司 苯并咪唑及其治疗糖尿病的用途
SG173312A1 (en) 2006-06-23 2011-08-29 Abbott Lab Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
MX2010001848A (es) * 2007-08-17 2010-03-10 Astrazeneca Ab Derivados de oxadiazol como inhibidores de diacilglicerolaciltrans ferasa (dgat).
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP2012512860A (ja) * 2008-12-19 2012-06-07 アストラゼネカ アクチボラグ １，３，４−オキサジアゾール誘導体および糖尿病を処置するそれらの使用
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
CA2764013A1 (en) * 2009-06-19 2010-12-23 Astrazeneca Ab Pyrazine carboxamides as inhibitors of dgat1
ES2523118T3 (es) 2009-11-05 2014-11-21 Fibrostatin, S.L. Inhibición de GPBP utilizando peptidomiméticos de Q2
EP2536283B8 (en) * 2010-02-18 2015-11-04 vTv Therapeutics LLC Phenyl-heteroaryl derivatives and methods of use thereof
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012162409A1 (en) * 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Biphenyl derivatives useful as glucagon receptor antagonists
WO2012165398A1 (ja) * 2011-05-30 2012-12-06 第一三共株式会社 シクロアルキルオキシビアリール型化合物
WO2013068328A1 (en) * 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
CN104245696A (zh) * 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
AU2013254307B2 (en) * 2012-04-27 2016-05-26 Novartis Ag Cyclic bridgehead ether DGAT1 inhibitors
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
CN105308026B (zh) * 2013-07-09 2018-12-21 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
CA2931313C (en) 2013-11-21 2022-04-05 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
ES2881706T3 (es) * 2014-03-12 2021-11-30 Astrazeneca Ab Método de tratamiento de las afecciones de la piel
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CA3101064A1 (en) * 2018-06-21 2019-12-26 Dermavant Sciences GmbH Topical formulations of dgat1 inhibitors and their methods of use
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7406566B2 (ja) * 2019-04-17 2023-12-27 イクシェル ファーマ エルエルシー フマル酸モノメチルのプロドラッグ

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3245989A (en) * 1962-12-15 1966-04-12 Acraf 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
US4983731A (en) 1989-03-17 1991-01-08 Nebraska Department Of Economic Development Separation and purification of sugar esters
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2000058491A1 (en) 1999-03-25 2000-10-05 The Kitasato Institute Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CA2369967A1 (en) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
JP2002284741A (ja) 2001-03-23 2002-10-03 Kitasato Inst:The ローズリピン誘導体
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
DE10223273A1 (de) 2002-05-24 2003-12-04 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA010859B1 (ru) * 2001-11-01 2008-12-30 Янссен Фармацевтика Н.В. Гетероариламины - производные пиримидина и пиридазина в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
WO2008011131A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
AU2003249937A1 (en) 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
CA2495903A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
ES2387803T3 (es) 2003-01-08 2012-10-02 Novartis Vaccines And Diagnostics, Inc. Agentes antibacterianos
EP1611120A4 (en) 2003-04-07 2008-04-23 Cortical Pty Ltd NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
US20050143464A1 (en) 2003-09-22 2005-06-30 Use-Techno Corporation Insulin secretion potentiator
BRPI0415500A (pt) 2003-10-17 2007-04-10 Incyte Corp hidroxamatos cìclicos substituìdos como inibidores de metaloproteinases de matriz
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP4820299B2 (ja) 2003-11-11 2011-11-24 ザ スキニー ドリンク カンパニー 肥満、心臓血管疾患及び冠状動脈疾患の予防及び治療のための組成物
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
JP2007519605A (ja) 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
US20070249620A1 (en) 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
ES2357015T3 (es) 2004-10-15 2011-04-15 Bayer Healthcare Llc Preparación y uso de derivados bifenil-4-ilcarbonilaminoácido para el tratamiento de la obesidad.
WO2006054370A1 (en) 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
JP2008523133A (ja) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
KR100883694B1 (ko) 2005-02-07 2009-02-12 에프. 호프만-라 로슈 아게 디아실글리세롤 아실트랜스퍼라제 억제제
AU2006236155A1 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
KR100910440B1 (ko) 2005-05-10 2009-08-04 에프. 호프만-라 로슈 아게 다이아실글리세롤 아실트랜스퍼레이즈 억제제
MX2007015759A (es) 2005-06-11 2008-02-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de diacilglicerol aciltransferasa (dgat).
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
US20100016295A1 (en) 2005-07-29 2010-01-21 Bayer Healthcare Llc Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
AU2006316560B2 (en) 2005-11-28 2011-06-16 Madrigal Pharmaceuticals, Inc. Inhibitors of diacyglycerol acyltransferase (DGAT)
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
WO2007074753A1 (ja) 2005-12-27 2007-07-05 Daiichi Sankyo Company, Limited 置換されたウレア誘導体を含有する医薬
EP2301923B1 (en) 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137103A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ATE492541T1 (de) 2006-05-30 2011-01-15 Astrazeneca Ab Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
JP2009539816A (ja) 2006-06-06 2009-11-19 アストラゼネカ アクチボラグ 化学化合物
CN101460492A (zh) 2006-06-08 2009-06-17 阿斯利康(瑞典)有限公司 苯并咪唑及其治疗糖尿病的用途
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611507D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US7569590B2 (en) 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
US8354432B2 (en) 2006-10-04 2013-01-15 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AU2007304365A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
NZ597247A (en) 2006-11-29 2013-06-28 Abbott Lab Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
BRPI0720023A2 (pt) 2006-12-11 2018-09-04 Novartis Ag método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1
US20100093733A1 (en) 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
KR20100017508A (ko) 2007-04-30 2010-02-16 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 1 효소의 억제제
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2010132590A (ja) 2008-12-03 2010-06-17 Astellas Pharma Inc オキサジアゾール化合物
JP2012512860A (ja) 2008-12-19 2012-06-07 アストラゼネカ アクチボラグ １，３，４−オキサジアゾール誘導体および糖尿病を処置するそれらの使用

Also Published As

Publication number Publication date
CN101932562A (zh) 2010-12-29
ZA201003979B (en) 2011-11-30
EP2234978A1 (en) 2010-10-06
CN101932562B (zh) 2013-06-12
DOP2010000192A (es) 2010-07-15
WO2009081195A1 (en) 2009-07-02
CA2707660A1 (en) 2009-07-02
JP5662803B2 (ja) 2015-02-04
AU2008339570A1 (en) 2009-07-02
ECSP10010274A (es) 2010-07-30
JP2011507823A (ja) 2011-03-10
EA201001015A1 (ru) 2011-02-28
CL2008003847A1 (es) 2009-11-27
IL206045A0 (en) 2010-11-30
ES2535083T3 (es) 2015-05-05
EP2234978B1 (en) 2015-02-25
NI201000108A (es) 2012-05-14
US7994179B2 (en) 2011-08-09
US20120108602A1 (en) 2012-05-03
NZ586104A (en) 2012-02-24
TW200932235A (en) 2009-08-01
US20090298853A1 (en) 2009-12-03
BRPI0821274A2 (pt) 2017-06-13
CO6290685A2 (es) 2011-06-20
KR20100099738A (ko) 2010-09-13
AU2008339570B2 (en) 2012-04-12
CR11518A (es) 2010-07-15
PE20091682A1 (es) 2009-12-04

Similar Documents

Publication Publication Date Title
AR069802A1 (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
HRP20130900T1 (hr) Derivat (aza)indola i njegova uporaba u medicinske svrhe
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
AR085586A1 (es) Derivados de acido 3-fenilpropionico ramificados y su uso como activador de sgc
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR066911A1 (es) Derivados de piperidina / piperazina
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR050953A1 (es) Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales
AR070801A1 (es) Derivados pirimidin -piridina
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
AR039125A1 (es) Derivados de piperidina o 8-aza-biciclo(3.2.1.)octa-3-il derivados, utiles como moduladores de receptores de actividad de quemoquinas
UY28094A1 (es) Derivados de la isoindolina
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR083723A1 (es) Inhibidores del virus de la hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal